Hamburg - Delayed Quote EUR
AbCellera Biologics Inc (8QQ.HM)
2.1850
-0.0430
(-1.93%)
At close: May 2 at 5:25:14 PM GMT+2
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
28,833
28,833
38,025
485,424
375,203
Cost of Revenue
--
--
--
66,436
45,516
Gross Profit
28,833
28,833
38,025
418,988
329,687
Operating Expense
329,979
329,979
261,077
191,923
107,788
Operating Income
-301,146
-301,146
-223,052
227,065
221,899
Net Non Operating Interest Income Expense
38,473
38,473
42,247
16,079
3,330
Other Income Expense
62,278
62,278
6,776
-4,045
-6,080
Pretax Income
-200,395
-200,395
-174,029
239,099
219,149
Tax Provision
-37,538
-37,538
-27,631
80,580
65,685
Net Income Common Stockholders
-162,857
-162,857
-146,398
158,519
153,464
Diluted NI Available to Com Stockholders
-162,857
-162,857
-146,398
158,519
153,464
Basic EPS
-0.61
-0.55
-0.51
0.56
0.56
Diluted EPS
-0.61
-0.55
-0.51
0.50
0.48
Basic Average Shares
293,051.7220
294,327.5320
289,166.4860
285,056.6060
275,763.7450
Diluted Average Shares
293,051.7220
294,327.5320
289,166.4860
314,827.2550
318,294.2360
Total Operating Income as Reported
-314,766
-314,766
-237,207
216,511
204,413
Total Expenses
329,979
329,979
261,077
258,359
153,304
Net Income from Continuing & Discontinued Operation
-162,857
-162,857
-146,398
158,519
153,464
Normalized Income
-162,857
-162,857
-146,398
158,519
153,464
Interest Income
38,473
38,473
42,247
16,079
3,330
Interest Expense
--
--
--
4,045
5,225
Net Interest Income
38,473
38,473
42,247
16,079
3,330
EBIT
-301,146
-301,146
-223,052
227,065
221,899
EBITDA
-204,148
-204,148
-192,158
260,167
239,149
Reconciled Cost of Revenue
--
--
--
61,177
42,717
Reconciled Depreciation
96,998
96,998
30,894
33,102
17,250
Net Income from Continuing Operation Net Minority Interest
-162,857
-162,857
-146,398
158,519
153,464
Total Unusual Items Excluding Goodwill
--
--
--
--
-855
Total Unusual Items
--
--
--
--
-855
Normalized EBITDA
-204,148
-204,148
-192,158
260,167
239,149
Tax Rate for Calcs
0.0002
0.0002
0.0002
0.0003
0.0003
12/31/2021 - 12/29/2020
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade